MedPath

Non Surgical Management for Uterine Residua After Pregnancy Termination, Abortion or Delivery

Phase 2
Terminated
Conditions
Intra-uterine Residua
Interventions
Registration Number
NCT01134926
Lead Sponsor
HaEmek Medical Center, Israel
Brief Summary

The aim of the study is to find out whether conservative treatment - expectant management or medical therapy using misoprostol is beneficial in the case of uterine residua, and which treatment is better.

Detailed Description

Retained products of conception are estimated to occur after approximately 1-6% of pregnancies, probably more often after termination of early pregnancies then after term pregnancy. Complication are abdominal pain, infection, bleeding and for the long term - intrauterine adhesions.Blood clots in the uterine cavity can cause similar complications. The definitive treatment is curettage or hysteroscopy, both of which are carried out under general anesthesia and require an operating theater. Although expectant management and uterotonic drugs are practically used in such situation, they are not described in the literature.This study compare between the outcome of misoprostol treatment and expectant management in the case of intrauterine residua after completion of pregnancy.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
23
Inclusion Criteria
  • women with sonographic examination reveals suspicion of intra-uterine residua after completion of pregnancy
  • intrauterine cavity, including endometrium, will be at least 15mm
Exclusion Criteria
  • the need for emergency surgical treatment (curettage)
  • fever - at least 38 celsius degree
  • women who had medical termination of pregnancy and the examination is after less then 2 weeks since treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intra-uterine residua. misoprostolmisoprostolThe patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
Primary Outcome Measures
NameTimeMethod
abscence of sonographic finding in the uterine cavityone week since recruitment

ofter one week, the patients will undergo an US examination.Failure of management defined as uterine cavity width \> 15mm

Secondary Outcome Measures
NameTimeMethod
ComplicationsWithin one week since recruitment

During the study,there will be collection of data considering pain, bleeding, infection and surgical evacuation.

Woman's satisfactionOne week since recruitment

At the end of the week, the patient will be asked about her satisfaction with the treatment

Trial Locations

Locations (1)

HaEmek medical center

🇮🇱

Afula, Israel

© Copyright 2025. All Rights Reserved by MedPath